Molecular implications of the PPARS in the diabetic eye

PPAR Research

Volumn , Issue , 2013, Pages

  Ciudin, Andreea ^a   Hernández, Cristina ^a   Simó, Rafael ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; CANDESARTAN; COLLAGEN TYPE 4; ENDOTHELIN 1; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 2; GLUTAMIC ACID; INSULIN; IRBESARTAN; LOSARTAN; MATRIX METALLOPROTEINASE; MURAGLITAZAR; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RETINOID X RECEPTOR; ROSIGLITAZONE; SIMVASTATIN; TESAGLITAZAR;

ADIPOCYTE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD RETINA BARRIER; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DRUG EFFICACY; FATTY ACID OXIDATION; GENETIC RISK; GLUCONEOGENESIS; HEART INFARCTION; HUMAN; LIPID METABOLISM; LIPOGENESIS; LOW LEVEL LASER THERAPY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROANGIOPATHY; MOLECULARLY TARGETED THERAPY; NERVE CELL; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA DEGENERATION; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK;

EID: 84874630344     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/686525     Document Type: Review

References (125)

1. Cheung N., Mitchell P., Wong T. Y., Diabetic retinopathy. The Lancet 2010 376 9735 124 136 2-s2.0-77955013602 10.1016/S0140-6736(09)62124-3
2. Klein R., Moss S. E., Klein B. E. K., Davis M. D., DeMets D. L., Wisconsin epidemiologic study of diabetic retinopathy. XII. Relationship of C-peptide and diabetic retinopathy. Diabetes 1990 39 11 1445 1450 2-s2.0-0025129904 (Pubitemid 20372236)
3. Tong L., Vernon S. A., Kiel W., Sung V., Orr G. M., Association of macular involvement with proliferative retinopathy in type 2 diabetes. Diabetic Medicine 2001 18 5 388 394 2-s2.0-0034913227 10.1046/j.1464-5491.2001.00483.x (Pubitemid 32679388)
4. Delcourt C., Massin P., Rosilio M., Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population. Diabetes and Metabolism 2009 35 6 431 438 2-s2.0-71449088916 10.1016/j.diabet.2009.06.002
5. Chen E., Looman M., Laouri M., Gallagher M., van Nuys K., Lakdawalla D., Fortuny J., Burden of illness of diabetic macular edema: literature review. Current Medical Research and Opinion 2010 26 7 1587 1597 2-s2.0-77953555650 10.1185/03007995.2010.482503
6. Lamoureux E. L., Wong T. Y., Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials. Diabetes Care 2011 34 4 1066 1067 2-s2.0-79956223912 10.2337/dc11-0225
7. Lee L. J., Yu A. P., Cahill K. E., Oglesby A. K., Tang J., Qiu Y., Birnbaum H. G., Direct and indirect costs among employees with diabetic retinopathy in the United States. Current Medical Research and Opinion 2008 24 5 1549 1559 2-s2.0-44349135017 10.1185/030079908X297303 (Pubitemid 351741588)
8. Pelletier E. M., Shim B., Ben-Joseph R., Caro J. J., Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics 2009 27 6 479 490 2-s2.0-68349109433 10.2165/00019053-200927060-00004
9. Heintz E., Wirehn A. B., Peebo B. B., Rosenqvist U., Levin L. A., Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010 53 10 2147 2154 2-s2.0-77958048810 10.1007/s00125-010-1836-3
10. Mohamed Q., Gillies M. C., Wong T. Y., Management of diabetic retinopathy: a systematic review. The Journal of the American Medical Association 2007 298 8 902 916 2-s2.0-34548087845 10.1001/jama.298.8.902 (Pubitemid 47311296)
11. Simó R., Hernández C., Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009 32 8 1556 1562 2-s2.0-68149131545 10.2337/dc09-0565
12. Sugden M. C., Caton P. W., Holness M. J., PPAR control: it's SIRTainly as easy as PGC. Journal of Endocrinology 2010 204 2 93 104 2-s2.0-75149194039 10.1677/JOE-09-0359
13. Lalwani N. D., Alvares K., Reddy M. K., Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proceedings of the National Academy of Sciences of the United States of America 1987 84 15 5242 5246 2-s2.0-0348232540 (Pubitemid 17129008)
14. Lalwani N. D., Fahl W. E., Reddy J. K., Detection of a nafenopin binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds. Biochemical and Biophysical Research Communications 1983 116 2 388 393 2-s2.0-0021060535 (Pubitemid 14242762)
15. Vamecq J., Latruffe N., Medical significance of peroxisome proliferator-activated receptors. The Lancet 1999 354 9173 141 148 2-s2.0-0033542873 10.1016/S0140-6736(98)10364-1 (Pubitemid 29313157)
16. Evans R. M., The steroid and thyroid hormone receptor superfamily. Science 1988 240 4854 889 895 2-s2.0-0023913120
17. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A. M., Saladin R., Najib J., Laville M., Fruchart J. C., Deeb S., Vidal-Puig A., Flier J., Briggs M. R., Staels B., Vidal H., Auwerx J., The organization, promoter analysis, and expression of the human PPAR γ gene. The Journal of Biological Chemistry 1997 272 30 18779 18789 2-s2.0-0030835678 10.1074/jbc.272.30.18779 (Pubitemid 27318225)
18. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α-β and-γ in the adult rat. Endocrinology 1996 137 1 354 366 2-s2.0-0030047806 10.1210/en.137.1.354 (Pubitemid 26005011)
19. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P., Staels B., Auwerx J., Laville M., Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 8 1319 1327 2-s2.0-0030747895 (Pubitemid 27315281)
20. Lemberger T., Braissant O., Juge-Aubry C., Keller H., Saladin R., Staels B., Auwerx J., Burger A. G., Meier C. A., Wahli W., PPAR tissue distribution and interactions with other hormone-signaling pathways. Annals of the New York Academy of Sciences 1996 804 231 251 2-s2.0-8044260810 10.1111/j.1749-6632.1996. tb18619.x (Pubitemid 27056613)
21. del V. Cano M., Gehlbach P. L., PPAR- α ligands as potential therapeutic agents for wet age-related macular degeneration. PPAR Research 2008 2008 5 2-s2.0-43949121929 10.1155/2008/821592 821592 (Pubitemid 351701947)
22. Bishop-Bailey D., PPARs and angiogenesis. Biochemical Society Transactions 2011 39 1601 1605 10.1042/BST20110643
23. Zhou J., Wilson K. M., Medh J. D., Genetic analysis of four novel peroxisome proliferator activated receptor- γ splice variants in monkey macrophages. Biochemical and Biophysical Research Communications 2002 293 1 274 283 2-s2.0-0036290825 10.1016/S0006-291X(02)00138-9 (Pubitemid 34694203)
24. Ding G., Fu M., Qin Q., Lewis W., Kim H. W., Fukai T., Bacanamwo M., Chen Y. E., Schneider M. D., Mangelsdorf D. J., Evans R. M., Yang Q., Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage. Cardiovascular Research 2007 76 2 269 279 2-s2.0-36649035297 10.1016/j.cardiores.2007.06.027 (Pubitemid 350198591)
25. Norris A. W., Chen L., Fisher S. J., Szanto I., Ristow M., Jozsi A. C., Hirshman M. F., Rosen E. D., Goodyear L. J., Gonzalez F. J., Spiegelman B. M., Kahn C. R., Muscle-specific PPAR γ -deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. The Journal of Clinical Investigation 2003 112 4 608 618 2-s2.0-0141831668 10.1172/JCI200317305 (Pubitemid 38056345)
26. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0 (Pubitemid 20356241)
27. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 5 649 688 2-s2.0-0033305213 (Pubitemid 30650602)
28. Kendall D. M., Rubin C. J., Mohideen P., Ledeine J. M., Belder R., Gross J., Norwood P., O'Mahony M., Sall K., Sloan G., Roberts A., Fiedorek F. T., DeFronzo R. A., Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α / γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006 29 5 1016 1023 2-s2.0-33745957332 10.2337/diacare.2951016 (Pubitemid 44115238)
29. Rizos C. V., Elisaf M. S., Mikhailidis D. P., Liberopoulos E. N., How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety 2009 8 1 15 32 2-s2.0-65649099536 10.1517/14740330802597821
30. Nissen S. E., Wolski K., Topol E. J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. The Journal of the American Medical Association 2005 294 20 2581 2586 2-s2.0-28144451163 10.1001/jama.294.20.joc50147 (Pubitemid 41697247)
31. Ratner R. E., Parikh S., Tou C., Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diabetes and Vascular Disease Research 2007 4 3 214 221 2-s2.0-34948873034 10.3132/dvdr.2007.042 (Pubitemid 47529211)
32. Dietz M., Mohr P., Kuhn B., Maerki H. P., Hartman P., Ruf A., Benz J., Grether U., Wright M. B., Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem 2012 7 6 1101 1111 10.1002/cmdc.201100598
33. Cavender M. A., Lincoff A. M., Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. American Journal of Cardiovascular Drugs 2010 10 4 209 216 2-s2.0-77954969340 10.2165/11539500-000000000-00000
34. Pershadsingh H. A., Moore D. M., PPAR γ agonists: potential as therapeutics for neovascular retinopathies. PPAR Research 2008 2008 13 2-s2.0-45349084588 10.1155/2008/164273 164273 (Pubitemid 351846741)
35. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., Hashiguchi Y., Sunagawa K., Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ Cardiovascular Research 2006 72 1 184 190 2-s2.0-33748947293 10.1016/j.cardiores.2006.07.014 (Pubitemid 44429904)
36. Erbe D. V., Gartrell K., Zhang Y. L., Suri V., Kirincich S. J., Will S., Perreault M., Wang S., Tobin J. F., Molecular activation of PPAR γ by angiotensin II type 1-receptor antagonists. Vascular Pharmacology 2006 45 3 154 162 2-s2.0-33750825285 10.1016/j.vph.2006.05.002 (Pubitemid 44716729)
37. Cariou B., Zair Y., Staels B., Bruckert E., Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011 34 9 2008 2014 10.2337/dc11-0093
38. Herzlich A. A., Ding X., Shen D., Ross R. J., Tuo J., Chan C. C., Peroxisome proliferator-activated receptor expression in murine models and humans with age-related macular degeneration. The Open Biology Journal 2009 2 141 148 10.2174/1874196700902010141
39. Dwyer M. A., Kazmin D., Hu P., McDonnell D. P., Malek G., Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration. Molecular Endocrinology 2011 25 2 360 372 2-s2.0-79951715828 10.1210/me.2010-0392
40. Qin S., McLaughlin A. P., De Vries G. W., Protection of RPE cells from oxidative injury by 15-deoxy-Δ 12,14-prostaglandin J2 by augmenting GSH and activating MAPK. Investigative Ophthalmology & Visual Science 2006 47 11 5098 5105 2-s2.0-34247141914 10.1167/iovs.06-0318 (Pubitemid 46586417)
41. Wang F., Gao L., Gong B., Hu J., Li M., Guan Q., Zhao J., Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Canadian Journal of Physiology and Pharmacology 2008 86 7 465 471 2-s2.0-46749157847 10.1139/Y08-043 (Pubitemid 351948686)
42. Tawfik A., Sanders T., Kahook K., Akeel S., Elmarakby A., Al-Shabrawey M., Suppression of retinal peroxisome proliferator-activated receptor γ in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase. Investigative Ophthalmology & Visual Science 2009 50 2 878 884 2-s2.0-59449102868 10.1167/iovs.08-2005
43. Costa V., Casamassimi A., Esposito K., Ciccodicola A., Villani A., Capone M., Iannella R., Schisano B., Ciotola M., Di Palo C., Capone Corrado F., Santangelo F., Giugliano D., Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. Journal of Biomedicine and Biotechnology 2009 2009 7 2-s2.0-58949092541 10.1155/2009/126917 126917
44. Petrovič M. G., Kunej T., Peterlin B., Dovč P., Petrovič D., Gly482Ser polymorphism of the peroxisome proliferator-activated receptor- γ coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPAR γ gene is not. Diabetes/Metabolism Research and Reviews 2005 21 5 470 474 2-s2.0-24944550759 10.1002/dmrr.546 (Pubitemid 41320659)
45. Hernandez C., Simo R., Neuroprotection in diabetic retinopathy. Current Diabetes Reports 2012 12 4 329 337 10.1007/s11892-012-0284-5
46. Simo R., Hernandez C., Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. British Journal of Ophthalmology 2012 96 10 1285 1290
47. Carrasco E., Hernández C., Miralles A., Huguet P., Farrés J., Simó R., Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 2007 30 11 2902 2908 2-s2.0-36048980250 10.2337/dc07-0332 (Pubitemid 350083143)
48. Garcia-Ramírez M., Hernández C., Villarroel M., Canals F., Alonso M. A., Fortuny R., Masmiquel L., Navarro A., García-Arumí J., Simó R., Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 2009 52 12 2633 2641 2-s2.0-70949094028 10.1007/s00125-009-1548-8
49. van Dijk H. W., Verbraak F. D., Kok P. H. B., Garvin M. K., Sonka M., Lee K., Devries J. H., Michels R. P. J., van Velthoven M. E. J., Schlingemann R. O., Abràmoff M. D., Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Investigative Ophthalmology & Visual Science 2010 51 7 3660 3665 2-s2.0-77955865169 10.1167/iovs.09-5041
50. Rungger-Brändle E., Dosso A. A., Leuenberger P. M., Glial reactivity, an early feature of diabetic retinopathy. Investigative Ophthalmology & Visual Science 2000 41 7 1971 1980 (Pubitemid 30354375)
51. Gerhardinger C., Costa M. B., Coulombe M. C., Toth I., Hoehn T., Grosu P., Expression of acute-phase response proteins in retinal Müller cells in diabetes. Investigative Ophthalmology & Visual Science 2005 46 1 349 357 2-s2.0-11144285028 10.1167/iovs.04-0860 (Pubitemid 40041218)
52. Lieth E., Barber A. J., Xu B., Dice C., Ratz M. J., Tanase D., Strother J. M., Glial reactivity and impaired glutamate metabolism in short- term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998 47 815 820 (Pubitemid 28201813)
53. Lieth E., LaNoue K. F., Antonetti D. A., Ratz M., Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Experimental Eye Research 2000 70 6 723 730 2-s2.0-0033843835 10.1006/exer.2000.0840
54. Kowluru R. A., Engerman R. L., Case G. L., Kern T. S., Retinal glutamate in diabetes and effect of antioxidants. Neurochemistry International 2001 38 5 385 390 2-s2.0-0035104682 10.1016/S0197-0186(00)00112-1 (Pubitemid 32166895)
55. Pulido J. E., Pulido J. S., Erie J. C., Arroyo J., Bertram K., Lu M. J., Shippy S. A., A role for excitatory amino acids in diabetic eye disease. Experimental Diabesity Research 2007 2007 7 2-s2.0-34547924445 10.1155/2007/36150 36150 (Pubitemid 47261553)
56. Ng Y. K., Zeng X. X., Ling E. A., Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Research 2004 1018 1 66 72 2-s2.0-3242688018 10.1016/j.brainres.2004.05. 055 (Pubitemid 38942862)
57. Santiago A. R., Gaspar J. M., Baptista F. I., Cristóvão A. J., Santos P. F., Kamphuis W., Ambrósio A. F., Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Molecular Vision 2009 15 1620 1630 2-s2.0-68949158370
58. Aoun P., Simpkins J. W., Agarwal N., Role of PPAR- γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Investigative Ophthalmology & Visual Science 2003 44 7 2999 3004 2-s2.0-0037562669 10.1167/iovs.02-1060 (Pubitemid 36759765)
59. Bernardo A., Levi G., Minghetti L., Role of the peroxisome proliferator-activated receptor- γ (PPAR- γ) and its natural ligand 15-deoxy-Δ(12,14)-prostaglandin J2 in the regulation of microglial functions. European Journal of Neuroscience 2000 12 7 2215 2223 2-s2.0-0033944415 10.1046/j.1460-9568.2000.00110.x (Pubitemid 30497019)
60. Bernardo A., Ajmone-Cat M. A., Gasparini L., Ongini E., Minghetti L., Nuclear receptor peroxisome proliferator-activated receptor- γ is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. Journal of Neurochemistry 2005 92 4 895 903 2-s2.0-13644260454 10.1111/j.1471-4159.2004.02932.x (Pubitemid 40229562)
61. Li P., Xu X., Zheng Z., Zhu B., Shi Y., Liu K., Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats. Current Eye Research 2011 36 7 673 679 2-s2.0-79958756508 10.3109/02713683.2011.572220
62. Fletcher E. L., Phipps J. A., Ward M. M., Vessey K. A., Wilkinson-Berka J. L., The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Progress in Retinal and Eye Research 2010 29 4 284 311 2-s2.0-77953479027 10.1016/j.preteyeres.2010.03.003
63. Sarlos S., Wilkinson-Berka J. L., The renin-angiotensin system and the developing retinal vasculature. Investigative Ophthalmology & Visual Science 2005 46 3 1069 1077 2-s2.0-16244376186 10.1167/iovs.04-0885 (Pubitemid 41321047)
64. Nagai N., Noda K., Urano T., Kubota Y., Shinoda H., Koto T., Shinoda K., Inoue M., Shiomi T., Ikeda E., Tsubota K., Suda T., Oike Y., Ishida S., Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Investigative Ophthalmology & Visual Science 2005 46 3 1078 1084 2-s2.0-20144389813 10.1167/iovs.04-1101 (Pubitemid 41321048)
65. Schupp M., Janke J., Clasen R., Unger T., Kintscher U., Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γ activity. Circulation 2004 109 17 2054 2057 2-s2.0-2442451618 10.1161/01.CIR.0000127955.36250.65 (Pubitemid 38620211)
66. Simó R., Villarroel M., Corraliza L., Hernández C., Garcia-Ramírez M., The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. Journal of Biomedicine and Biotechnology 2010 2010 15 190724 2-s2.0-77953170750 10.1155/2010/190724
67. Ershov A. V., Bazan N. G., Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells. Journal of Neuroscience Research 2000 60 328 337 (Pubitemid 30253596)
68. Toda N., Nakanishi-Toda M., Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Progress in Retinal and Eye Research 2007 26 3 205 238 2-s2.0-33947703167 10.1016/j.preteyeres.2007.01.004 (Pubitemid 46498800)
69. Ergul A., Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacological Research 2011 63 6 477 482 2-s2.0-79958046949 10.1016/j.phrs.2011.01.012
70. Kim J., Oh Y. S., Shinn S. H., Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes. Experimental Eye Research 2005 81 1 65 70 2-s2.0-20544434995 10.1016/j.exer.2005.01.010 (Pubitemid 40840547)
71. Omae T., Nagaoka T., Tanano I., Yoshida A., Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Investigative Ophthalmology & Visual Science 2011 52 9 6749 6756 10.1167/iovs.10-6826
72. Satoh H., Tsukamoto K., Hashimoto Y., Hashimoto N., Togo M., Hara M., Maekawa H., Isoo N., Kimura S., Watanabe T., Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR γ on vascular endothelial function. Biochemical and Biophysical Research Communications 1999 254 3 757 763 2-s2.0-0033608242 10.1006/bbrc.1998.0126 (Pubitemid 29290541)
73. Ray D., Mishra M., Ralph S., Read I., Davies R., Brenchley P., Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004 53 3 861 864 2-s2.0-1442349965 10.2337/diabetes.53.3.861 (Pubitemid 38270661)
74. Colucciello M., Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Archives of Ophthalmology 2005 123 9 1273 1275 2-s2.0-24944572295 10.1001/archopht.123.9.1273 (Pubitemid 41316750)
75. Ryan E. H. Jr., Han D. P., Ramsay R. C., Cantrill H. L., Bennett S. R., Dev S., Williams D. F., Diabetic macular edema associated with glitazone use. Retina 2006 26 5 562 570 2-s2.0-33745782356 10.1097/00006982-200605000-00011 (Pubitemid 44620399)
76. Niemeyer N. V., Janney L. M., Thiazolidinedione-induced edema. Pharmacotherapy 2002 22 7 924 929 2-s2.0-0035990404 (Pubitemid 34743442)
77. Fong D. S., Contreras R., Glitazone use associated with diabetic macular edema. American Journal of Ophthalmology 2009 147 4 583.e1 586.e1 2-s2.0-62649174048 10.1016/j.ajo.2008.10.016
78. Idris I., Warren G., Donnelly R., Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Archives of Internal Medicine 2012 172 13 1005 1011 10.1001/archinternmed.2012. 1938
79. Ambrosius W. T., Danis R. P., Goff D. C. Jr., Greven C. M., Gerstein H. C., Cohen R. M., Riddle M. C., Miller M. E., Buse J. B., Bonds D. E., Peterson K. A., Rosenberg Y. D., Perdue L. H., Esser B. A., Seaquist L. A., Felicetta J. V., Chew E. Y., Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Archives of Ophthalmology 2010 128 3 312 318 2-s2.0-77949294909 10.1001/archophthalmol.2009.310
80. Colucciello M., Ryan E., Macular edema and thiazolidinediones. Archives of Ophthalmology 2010 128 12 1630 1631 2-s2.0-78650117791 10.1001/ archophthalmol.2010.287
81. Muranaka K., Yanagi Y., Tamaki Y., Usui T., Kubota N., Iriyama A., Terauchi Y., Kadowaki T., Araie M., Effects of peroxisome proliferator-activated receptor γ and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Investigative Ophthalmology & Visual Science 2006 47 10 4547 4552 2-s2.0-33750598226 10.1167/iovs.05-1432 (Pubitemid 46579384)
82. Zheng Z., Chen H., Wang H., Ke B., Zheng B., Li Q., Li P., Su L., Gu Q., Xu X., Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor γ coactivator 1 α Diabetes 2010 59 9 2315 2325 2-s2.0-77956369911 10.2337/db10-0638
83. Coletta D. K., Sriwijitkamol A., Wajcberg E., Tantiwong P., Li M., Prentki M., Madiraju M., Jenkinson C. P., Cersosimo E., Musi N., DeFronzo R. A., Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 2009 52 4 723 732 2-s2.0-61449222837 10.1007/s00125-008-1256-9
84. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., Nishizawa Y., Peroxisome proliferator-activated receptor- γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochemical and Biophysical Research Communications 2000 271 3 571 574 2-s2.0-0034685660 10.1006/bbrc.2000.2665 (Pubitemid 30444669)
85. Emoto M., Anno T., Sato Y., Tanabe K., Okuya S., Tanizawa Y., Matsutani A., Oka Y., Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001 50 5 1166 1170 2-s2.0-0035029848 (Pubitemid 32374549)
86. Chintalgattu V., Harris G. S., Akula S. M., Katwa L. C., PPAR- γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovascular Research 2007 74 1 140 150 2-s2.0-33847674375 10.1016/j.cardiores.2007.01.010 (Pubitemid 46366953)
87. Murata T., Hata Y., Ishibashi T., Kim S., Hsueh W. A., Law R. E., Hinton D. R., Response of experimental retinal neovascularization to thiazolidinediones. Archives of Ophthalmology 2001 119 5 709 717 2-s2.0-0035013061 (Pubitemid 32417377)
88. Aljada A., O'Connor L., Fu Y. Y., Mousa S. A., PPAR γ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 2008 11 4 361 367 2-s2.0-58149335340 10.1007/s10456-008-9118-0
89. Higuchi A., Ohashi K., Shibata R., Sono-Romanelli S., Walsh K., Ouchi N., Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 1 46 53 2-s2.0-73849143594 10.1161/ATVBAHA.109.198465
90. Rodrigues G. A., Maurier-Mahé F., Shurland D. L., McLaughlin A., Luhrs K., Throo E., Delalonde-Delaunay L., Pallares D., Schweighoffer F., Donello J., Differential effects of PPAR γ ligands on oxidative stress-induced death of retinal pigmented epithelial cells. Investigative Ophthalmology & Visual Science 2011 52 2 890 903 2-s2.0-79953276843 10.1167/iovs.10-5715
91. Hatanaka H., Koizumi N., Okumura N., Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF- β are prevented by PPAR- γ agonists. Investigative Ophthalmology & Visual Science 2012 53 11 6955 6963 10.1167/iovs.12-10488
92. Shen L. Q., Child A., Weber G. M., Folkman J., Aiello L. P., Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Archives of Ophthalmology 2008 126 6 793 799 2-s2.0-45149096016 10.1001/archopht.126.6. 793 (Pubitemid 351831328)
93. Pasceri V., Wu H. D., Willerson J. T., Yeh E. T. H., Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor- γ activators. Circulation 2000 101 3 235 238 2-s2.0-0034711678 (Pubitemid 30054148)
94. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation. Nature 1998 391 6662 79 82 2-s2.0-0031886864 10.1038/34178 (Pubitemid 28079218)
95. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J. W., Wright S. D., Cai T. Q., Activation of PPAR α or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochemical and Biophysical Research Communications 2000 267 1 345 349 2-s2.0-0034614270 10.1006/bbrc.1999.1968 (Pubitemid 30072554)
96. Ishizuka T., Itaya S., Wada H., Ishizawa M., Kimura M., Kajita K., Kanoh Y., Miura A., Muto N., Yasuda K., Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998 47 9 1494 1500 2-s2.0-0031685956 (Pubitemid 28396955)
97. Harrold B. P., Marmion V. J., Gough K. R., A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969 18 5 285 291 2-s2.0-0014519590
98. Dorne P. A., Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years. Archives d'Ophtalmologie 1977 37 5 393 400 2-s2.0-17744402260 (Pubitemid 8118971)
99. Keech A., Simes R. J., Barter P., Best J., Scott R., Taskinen M. R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y. A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005 366 9500 1849 1861 10.1016/S0140-6736(05)67667-2 (Pubitemid 41690113)
100. Keech A. C., Mitchell P., Summanen P. A., O'Day J., Davis T., Moffitt M., Taskinen M. R., Simes R., Tse D., Williamson E., Merrifield A., Laatikainen L., d'Emden M., Crimet D., O'Connell R., Colman P., Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet 2007 370 9600 1687 1697 2-s2.0-36049001784 10.1016/S0140-6736(07)61607-9 (Pubitemid 350100775)
101. Chew E. Y., Ambrosius W. T., Davis M. D., Danis R. P., Gangaputra S., Greven C. M., Hubbard L., Esser B. A., Lovato J. F., Perdue L. H., Goff D. C., Cushman W. C., Ginsberg H. N., Elam M. B., Genuth S., Gerstein H. C., Schubart U., Fine L. J., Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England Journal of Medicine 2010 363 3 233 244 2-s2.0-77954654472 10.1056/NEJMoa1001288
102. Simó R., Hernández C., Fenofibrate for diabetic retinopathy. The Lancet 2007 370 9600 1667 1668 2-s2.0-36048985669 10.1016/S0140-6736(07)61608-0 (Pubitemid 350100776)
103. Ginsberg H. N., Elam M. B., Lovato L. C., Crouse J. R., Leiter L. A., Linz P., Friedewald W. T., Buse J. B., Gerstein H. C., Probstfield J., Grimm R. H., Ismail-Beigi F., Bigger J. T., Goff D. C., Cushman W. C., Simons-Morton D. G., Byington R. P., Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010 362 17 1563 1574 2-s2.0-77951704587 10.1056/NEJMoa1001282
104. García-Ramírez M., Canals F., Hernández C., Colomé N., Ferrer C., Carrasco E., García-Arumí J., Simó R., Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007 50 6 1294 1303 2-s2.0-34247877623 10.1007/s00125-007-0627-y (Pubitemid 46701542)
105. Simo R., Garcia-Ramirez M., Higuera M., Hernandez C., Apolipoprotein A1 is overexpressed in the retina of diabetic patients. American Journal of Ophthalmology 2009 147 2 319.e1 325.e1 10.1016/j.ajo.2008.08.009
106. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J. C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 98 19 2088 2093 2-s2.0-0032506273 (Pubitemid 28512236)
107. Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., Yokoyama S., Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1193 1197 2-s2.0-20144373625 10.1161/01.ATV.0000163844.07815.c4 (Pubitemid 40776608)
108. Sasongko M. B., Wong T. Y., Nguyen T. T., Shaw J. E., Jenkins A. J., Wang J. J., Novel versus traditional risk markers for diabetic retinopathy. Diabetologia 2012 55 3 666 670 10.1007/s00125-011-2424-x
109. Bordet R., Ouk T., Petrault O., Gelé P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J. C., Bastide M., PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society Transactions 2006 34 6 1341 1346 2-s2.0-34147182536 10.1042/BST0341341 (Pubitemid 46769051)
110. Murakami H., Murakami R., Kambe F., Cao X., Takahashi R., Asai T., Hirai T., Numaguchi Y., Okumura K., Seo H., Murohara T., Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochemical and Biophysical Research Communications 2006 341 4 973 978 2-s2.0-32344453963 10.1016/j.bbrc.2006.01.052 (Pubitemid 43221761)
111. Zanetti M., Stocca A., Dapas B., Farra R., Uxa L., Bosutti A., Barazzoni R., Bossi F., Giansante C., Tedesco F., Cattin L., Guarnieri G., Grassi G., Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. Journal of Molecular Medicine 2008 86 2 185 195 2-s2.0-38649101592 10.1007/s00109-007-0257-3 (Pubitemid 351172121)
112. Tomizawa A., Hattori Y., Inoue T., Hattori S., Kasai K., Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 2011 60 4 513 522 2-s2.0-79952986434 10.1016/j.metabol.2010.04.020
113. Kim J., Ahn J. H., Kim J. H., Yu Y. S., Kim H. S., Ha J., Shinn S. H., Oh Y. S., Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Experimental Eye Research 2007 84 5 886 893 2-s2.0-34247108235 10.1016/j.exer.2007.01.009 (Pubitemid 46590130)
114. Miranda S., Gonzalez-Rodriguez A., Garcia-Ramirez M., Revuelta-Cervantes J., Hernandez C., Simo R., Valverde A. M., Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. Journal of Cellular Physiology 2012 227 6 2352 2362
115. Antonetti D. A., Klein R., Gardner T. W., Diabetic retinopathy. The New England Journal of Medicine 2012 366 1227 1239 10.1056/NEJMra1005073
116. Chinetti G., Griglio S., Antonucci M., Torra I. P., Delerive P., Majd Z., Fruchart J. C., Chapman J., Najib J., Staels B., Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. The Journal of Biological Chemistry 1998 273 40 25573 25580 2-s2.0-0032475922 10.1074/jbc.273.40.25573 (Pubitemid 28475776)
117. Israelian-Konaraki Z., Reaven P. D., Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005 103 1 1 9 2-s2.0-9144271375 10.1159/000081845 (Pubitemid 39541239)
118. Villarroel M., Garcia-Ramirez M., Corraliza L., Hernandez C., Simo R., Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011 54 6 1543 1553 10.1007/s00125-011-2089-5
119. Trudeau K., Roy S., Guo W., Hernandez C., Villarroel M., Simo R., Roy S., Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Investigative Ophthalmology & Visual Science 2011 52 6348 6354 10.1167/iovs.11-7282
120. Inoue I., Shino K., Noji S., Awata T., Katayama S., Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochemical and Biophysical Research Communications 1998 246 2 370 374 2-s2.0-0032546485 10.1006/bbrc.1998.8622 (Pubitemid 28412605)
121. Meissner M., Stein M., Urbich C., Reisinger K., Suske G., Staels B., Kaufmann R., Gille J., PPAR α activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circulation Research 2004 94 3 324 332 2-s2.0-1242297567 10.1161/01.RES.0000113781.08139.81 (Pubitemid 38240723)
122. Varet J., Vincent L., Mirshahi P., Pille J. V., Legrand E., Opolon P., Mishal Z., Soria J., Li H., Soria C., Fenofibrate inhibits angiogenesis in vitro and in vivo. Cellular and Molecular Life Sciences 2003 60 4 810 819 2-s2.0-0038702371 10.1007/s00018-003-2322-6 (Pubitemid 36570772)
123. Yokoyama Y., Xin B., Shigeto T., Umemoto M., Kasai-Sakamoto A., Futagami M., Tsuchida S., Al-Mulla F., Mizunuma H., Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer. Molecular Cancer Therapeutics 2007 6 4 1379 1386 2-s2.0-34248199412 10.1158/1535-7163.MCT-06-0722 (Pubitemid 46712001)
124. Chen Y., Hu Y., Lin M., Jenkins A. J., Keech A. C., Mott R., Lyons T. J., Ma J. X., Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013 62 1 261 272 10.2337/db11-0413
125. Stephen R. L., Gustafsson M. C. U., Jarvis M., Tatoud R., Marshall B. R., Knight D., Ehrenborg E., Harris A. L., Wolf C. R., Palmer C. N. A., Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Research 2004 64 9 3162 3170 2-s2.0-2342640982 10.1158/0008-5472.CAN-03-2760 (Pubitemid 38581418)